Andreas Meisel

About Andreas Meisel

Andreas Meisel, With an exceptional h-index of 72 and a recent h-index of 47 (since 2020), a distinguished researcher at Charité - Universitätsmedizin Berlin,

His recent articles reflect a diverse array of research interests and contributions to the field:

Exploring the depths of IgG4: insights into autoimmunity and novel treatments

Long-term Efficacy and Safety of Ravulizumab, a Long-acting Terminal Complement Inhibitor, in Adults with Anti-acetylcholine Receptor Antibody-positive Generalized Myasthenia …

Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis

Functional Signature of LRP4 Antibodies in Myasthenia Gravis

Pregnancy in myasthenia gravis: a retrospective analysis of maternal and neonatal outcome from a large tertiary care centre in Germany

A supervised, externally validated machine learning model for artifact and drainage detection in high-resolution intracranial pressure monitoring data

Myasthenia gravis–Schritt für Schritt

Burden of disease in Lambert-Eaton myasthenic syndrome: taking the patient’s perspective

Andreas Meisel Information

University

Position

___

Citations(all)

22792

Citations(since 2020)

9642

Cited By

16475

hIndex(all)

72

hIndex(since 2020)

47

i10Index(all)

216

i10Index(since 2020)

171

Email

University Profile Page

Google Scholar

Top articles of Andreas Meisel

Exploring the depths of IgG4: insights into autoimmunity and novel treatments

2024/4/18

Andreas Meisel
Andreas Meisel

H-Index: 44

Long-term Efficacy and Safety of Ravulizumab, a Long-acting Terminal Complement Inhibitor, in Adults with Anti-acetylcholine Receptor Antibody-positive Generalized Myasthenia …

2022/5/3

James F Howard
James F Howard

H-Index: 23

Andreas Meisel
Andreas Meisel

H-Index: 44

Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis

European Journal of Neurology

2024/3/24

Andreas Meisel
Andreas Meisel

H-Index: 44

Functional Signature of LRP4 Antibodies in Myasthenia Gravis

Neurology: Neuroimmunology & Neuroinflammation

2024/3/20

Heinz Wiendl
Heinz Wiendl

H-Index: 55

Andreas Meisel
Andreas Meisel

H-Index: 44

Pregnancy in myasthenia gravis: a retrospective analysis of maternal and neonatal outcome from a large tertiary care centre in Germany

Archives of Gynecology and Obstetrics

2024/3/16

Andreas Meisel
Andreas Meisel

H-Index: 44

Stefan Verlohren
Stefan Verlohren

H-Index: 29

A supervised, externally validated machine learning model for artifact and drainage detection in high-resolution intracranial pressure monitoring data

Journal of Neurosurgery

2024/3/15

Myasthenia gravis–Schritt für Schritt

Neurologie up2date

2024/3

Andreas Meisel
Andreas Meisel

H-Index: 44

Burden of disease in Lambert-Eaton myasthenic syndrome: taking the patient’s perspective

Journal of Neurology

2024/2/29

Andreas Meisel
Andreas Meisel

H-Index: 44

Myasthenia Gravis: Utilising cross-platform quantitative content analysis to uncover and validate unmet needs

2024/2/28

David Legg
David Legg

H-Index: 15

Andreas Meisel
Andreas Meisel

H-Index: 44

Identifying patients at risk for myasthenic crisis with hemogram and inflammation-related laboratory parameters–a pilot study

Frontiers in Neurology

2024/2/26

Andreas Meisel
Andreas Meisel

H-Index: 44

Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study

Muscle & Nerve

2024/2/21

POLAR: prediction of prolonged mechanical ventilation in patients with myasthenic crisis

Journal of Neurology

2024/2/8

Dominik Heider
Dominik Heider

H-Index: 21

Andreas Meisel
Andreas Meisel

H-Index: 44

Machine learning using multimodal and autonomic nervous system parameters predicts clinically apparent stroke-associated pneumonia in a development and testing study

Journal of Neurology

2024/2

Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis

Frontiers in Neurology

2024/1/17

Andreas Meisel
Andreas Meisel

H-Index: 44

Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study

Journal of Clinical Neuroscience

2024/1/1

Andreas Meisel
Andreas Meisel

H-Index: 44

Weaning and extubation failure in myasthenic crisis: a multicenter analysis

Journal of Neurology

2024/1

Classifying the risk for myasthenic crisis using data-driven explainable machine learning with informative feature design and variance control-a pilot study

medRxiv

2023

Andreas Meisel
Andreas Meisel

H-Index: 44

Concordance between patient-and physician-reported Myasthenia Gravis Activities of Daily Living (MG-ADL) scores

2023

Andreas Meisel
Andreas Meisel

H-Index: 44

Patient-reported impact of myasthenia gravis in the real world: findings from a digital observational survey-based study (MyRealWorld MG)

Bmj Open

2023/5/1

Andreas Meisel
Andreas Meisel

H-Index: 44

Fatemeh Amini
Fatemeh Amini

H-Index: 1

Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG

BMJ open

2023/1/1

Andreas Meisel
Andreas Meisel

H-Index: 44

See List of Professors in Andreas Meisel University(Charité - Universitätsmedizin Berlin)

Co-Authors

academic-engine